rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Sarcopenia in Chronic Lung Diseases
Status: Recruiting

Inclusion criteria A)Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.

B) Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment. Those who meet the conditions for frailty diagnosis after assessment by the Frailty Scale Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources Age>=20  Exclusion Criteria:  Patients who refuse to sign the consent form Patients who are bed ridden or unable to walk due to physical disabilities Patients with terminal cancer or human acquired immunodeficiency syndrome Patients with edema (grading pitting edema +2) - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Baseline demographic characteristic, health behavior and exercise habits are collected by questionnaires. The main disease diagnosis, medication, clinical assessment questionnaire or biochemical examination and radiological examination results in this inpatient and outpatient visit are collected. Three tools are used to prescreen the candidates, which are SARC-Calf questionnaire, frailty index According to the 2019 Asian Sarcopenia Consensus, participants are examined by SARC-Calf questionnaire, grip strength test and a physical performance test, including sit-stand test, short physical performance battery (SPPB), gait speed test and six-minute walk test. Afterward, bioelectrical impedance analysis (BIA) and Dual-energy X-ray absorptiometry (DXA) are applied to all participants by to analyze body composition. Participants are classified into Sarcopenia group and severe Sarcopenia group. Research nurse provides health education to participants after the assessment. - SamplingMethod: Non-Probability Sample
Vascular Affection in Behcet Disease
Status: Not yet recruiting

To measure the level of serum elafin in patients with behcet disease and to assess the correlation between serum elafin and vascular affection and their relation with disease activity

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  patients diagnosed as behcet disease Age (20-45)  Exclusion Criteria:  age <20 and >45 Other autoimmune diseases Risk factors (ischemic heart disease, diabetes) Chronic conditions (malignancy, chronic kidney disease) - Gender: All - MinimumAge: 20 Years - MaximumAge: 45 Years - StdAgeList: Adult - StudyPopulation: 45 patients with behcet disease aged(20-45) in comparison with 45 heathy participant s - SamplingMethod: Non-Probability Sample
Unreamed Intramedullary Tibial Nailing in Treatment of Open IIIa Diaphyseal Tibial Fractures in Adults
Status: Not yet recruiting

To study the incidence of non union of Unreamed intramedullary nailing in type IIIa Open diaphyseal fractures of the tibia as a primary outcome and the incidence of complications and clinical and functional outcome as a secondary outcome .

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Open grade IIIa diaphyseal tibial fractures . Skeletaly mature patients .  Exclusion Criteria:  late presentation and open infected fractures . Associated intraarticular fractures of proximal /distal tibia. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Adult patients presenting with type IIIa diaphyseal tibial fractures are included in the study - SamplingMethod: Non-Probability Sample
Body First Approach in Lap Cholecystectomy in Cases With Obscure Calot's Triangle
Status: Not yet recruiting

The aim of this study is to evaluate the body first approach on the rate of conversion to open technique & VBI in patients with obscure calot's triangle.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - All adult patients aging above 18 years old fit for (LC), who presented with symptomatic gall stones by clinical examination and detected by preoperative imaging and intra-operatively have obscure Calot's triangle.  Exclusion Criteria:  unfit patients. Patients with calcular obstructive jaundice. - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult - StudyPopulation: All adult patients aging above 18 years old fit for (LC), who presented with symptomatic gall stones by clinical examination and detected by preoperative imaging and intra-operatively have obscure Calot's triangle. - SamplingMethod: Non-Probability Sample
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Status: Recruiting

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).

Study details include:

The study duration (screening, 24-52-week treatment, 20-week safety follow-up) will be up to 47-77 weeks.
The treatment duration will be up to 24-52 weeks.
The follow-up duration will be 20 weeks.
Site/phone visits are at a monthly interval.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participant must be 18 to 85 years of age inclusive. Clinical history consistent with NCFB (cough, chronic sputum production and/or recurrent respiratory infections). Participants with a FEV1 % predicted ≥30%. Participants with at least 2 moderate or 1 severe Pulmonary exacerbations (PEs) in the past 12 months.  Exclusion Criteria:  Participants are excluded from the study if any of the following criteria apply:  Have bronchiectasis due to CF, hypogammaglobulinemia, common variable immunodeficiency, known active nontuberculous mycobacteria (NTM) lung infection, or pulmonary fibrosis. Known or suspected immunodeficiency disorder. Pulmonary exacerbation which has not resolved clinically during screening period. Have significant haemoptysis. Have any clinically significant abnormal laboratory values at Screening or diseases or disorders. History of lung transplantation. History of malignancy within 5 years before Screening, or during the screening period Currently being treated with antimicrobial therapy for tuberculosis (TB). Currently on active treatment for allergic bronchopulmonary aspergillosis (ABPA). Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease Known allergy to itepekimab or to excipients Live-attenuated vaccine(s) within 4 weeks prior to Screening or plans to receive such vaccines during the study Unstable ischemic heart disease Cardiomyopathy or other relevant cardiovascular disorder Clinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Screening.  The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
A Phase I/II Clinical Study of the KL003 Cell Injection in β-Thalassemia Major Participants
Status: Not yet recruiting

This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female age between 3-35 years; Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years; Karnofsky performance status ≥70 for participants≥16 years of age; Lansky performance status of ≥70 for participants<16 years of age; Eligible to undergo auto-HSCT; Willing and able to follow the research procedures and conditions, with good compliance; Willing to receive at least the 2 years follow-up; Participant and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form.  Exclusion Criteria:  Diagnosis of composite α thalassemia; Prior receipt of gene therapy or allo-HSCT; Meet the criteria for allo-HSCT and with an identified willing donor with full HLA match; Participants with severe iron overload at the time of screening; Presence of unusual antibody of red blood cell antigens or tested positive for platelet antibody; Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.); Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator; Subjects positive with the following etiological tests: human immunodeficiency virus(HIV-1-2),human cytomegalovirus (HCMV-DNA),EB virus（EBV-DNA）,HBV (HBsAg/HBV-DNA positive),HCV antibody (HCV-Ab), Human T-lymphotropic virus antibody (HTLV-Ab), Treponema pallidum antibody (TP-Ab); Uncorrectable coagulation dysfunction or history of severe bleeding disorder;  History of major organ damage including:  Liver function test suggest AST or ALT levels >3× upper limit of normal（ULN）; Total serum bilirubin value>2.5×ULN;if combined with Gilbert syndrome, total bilirubin>3×ULN and direct bilirubin value>2.5×ULN; Left ventricular ejection fraction <45%; Baseline calculated eGFR<60mL/min/1.73m2; Pulmonary function:FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction; - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Years - MaximumAge: 35 Years - StdAgeList: Child, Adult
MWM Technique in Patients With Knee OA
Status: Recruiting

The aim of this study is to investigate the effect of the MWM technique on pain, normal joint movement, proprioception and quality of life in patients with knee osteoarthritis (OA).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  being diagnosed with knee osteoarthritis, being diagnosed with knee OA at the earliest 6 months ago  Exclusion Criteria:  Participants who were pregnant, had knee surgery, had an infection, had a pacemaker, had an infraction, had cancer, or were receiving corticosteroid treatment were excluded from the study - HealthyVolunteers: No - Gender: All - MinimumAge: 25 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Robotic Assisted vs Custom Made Total Knee Arthroplasty
Status: Recruiting

The goal of this clinical trial is to compare Robotic Assisted, functionally aligned vs Custom Made Total Knee Arthroplasty in patients with knee osteoarthritis. The main questions it aims to answer are:

Which implant/philosophy yields better clinical outcomes?
Which implant/philosophy yields better satisfaction?
Which system is more OR efficient? Participants will be followed for 2 years postoperatively.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - The patient is a male or non-pregnant female between the ages of 40 and 90 years The patient requires a primary total knee replacement Patient is deemed appropriate for a cruciate retaining knee replacement The patient has a primary diagnosis of osteoarthritis (OA) The patient has intact collateral ligaments The patient is able to undergo CT scanning of the affected limb The patient has signed the study specific, ethics-approved, informed consent document The patient is willing and able to comply with the specified pre-operative and post-operative clinical and radiographic evaluations  Exclusion Criteria:  - The patient has a history of total, unicompartmental reconstruction or fusion of the affected joint Patient has had a previous osteotomy around the knee The patient is morbidly obese (BMI > 41) The patient has a deformity which will require the use of stems, wedges or augments The patient has a varus deformity ≥ 15° The patient has a valgus deformity >3° The patient has a neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device The patient is unable to speak German The patient is pregnant - HealthyVolunteers: No - Gender: All - MinimumAge: 40 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult
Food Cravings Strategies During Dietary Weight Loss
Status: Recruiting

The purpose is to optimize the EMPOWER program by integrating strategies to reduce food cravings, a critical yet often overlooked factor for long-term success in weight management.

The objective of this study is to determine the efficacy of craving coping strategies on weight loss outcomes by conducting a randomized controlled trial. Participants will be randomized to receive one of the two strategies to manage food cravings.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult between the ages of 18 and 75 BMI of at least 28 and above  4- Have access to the internet 3- Report experiencing at least a moderate amount of food cravings, and they consume the craved food at least a few times per week.  Exclusion Criteria:  Participation in a formal weight management program within the preceding three months. Usage of medications impacting weight. Being pregnant or breastfeeding. Having a history of bariatric surgeries. Diagnosed with DM type 1 or/and Use insulin injection - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Multi-disciplinary Care for Brain Metastases
Status: Recruiting

This is a health services intervention study aimed at understanding the impact of intensive multi-disciplinary care compared with standard care on patient-reported symptom outcomes and prognostic awareness in patients with brain metastases.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients of all genders must be at least 18 years of age. Patients must have histologically confirmed, newly diagnosed brain metastases from known or suspected solid tumor primary neoplasms. Patients must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact). Patients must be able to complete questionnaires in English. Patients must have the ability to provide informed consent.  Exclusion Criteria:  Patients who are < 18 years of age are not eligible. Patients who are Pregnant are not eligible. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
PET Imaging of Fibroblast Activation in Atherosclerosis
Status: Recruiting

Fibroblast activation protein (FAP) is a fibroblast-specific marker expressed in atherosclerosis, associated with endothelial-to-mesenchymal transition and a rupture-prone plaque phenotype. This study aims to evaluate in-vivo fibroblast activation in carotid and coronary atherosclerotic diseases with FAPI PET and its correlation with histological vulnerability and clinical outcome.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  For the carotid stenosis group: patients with symptomatic carotid stenosis with >50% stenosis on carotid CTA; OR patients with unsymptomatic carotid stenosis with >70% stenosis on carotid CTA For CAD group: patients with stable ischemic heart disease OR acute coronary syndrome, including ST-elevation MId, non-ST elevation MI, and unstable angina signed informed consent  Exclusion Criteria:  Pregnancy, lactation, or intention to become pregnant during the study Contradiction to MRI or CTA - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with carotid stenosis or CAD. - SamplingMethod: Non-Probability Sample
Metformin Use in Patients Undergoing Total Joint Replacement Surgery
Status: Not yet recruiting

The goal of this pilot, randomized, single-blind, placebo-controlled trial is to evaluate the feasibility of and provide preliminary information for a multi-center randomized controlled trial that will assess the effects of metformin on blood sugar control in patients after total hip or total knee replacement surgery.

The primary objective of this study is to assess the feasibility of conducting a large, randomized trial with regards to timely recruitment, study drug administration, protocol adherence, and overall retention in patients undergoing total joint arthroplasty.

Secondarily, the investigators aim to obtain preliminary estimates of group-specific outcome means and variances for primary and secondary outcomes of a larger future trial.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female, age 18-99 years Undergoing total hip or total knee arthroplasty, including elective, primary, and revision surgeries Ability to take oral medication and be willing to adhere to the prescribed metformin regimen regardless of current, past, or no metformin use.  Note: Patients with or without type 2 diabetes are considered eligible. (E.g.)  Type 2 diabetic on metformin Type 2 diabetic on metformin and other medication, including insulin Type 2 diabetic on medication but not metformin Pre-diabetic Non-diabetic  Exclusion Criteria:  Advanced renal insufficiency (glomerular filtration rate (GFR) < 45, or chronic kidney disease (CKD) stage 3B or higher) Advanced liver cirrhosis or failure (Child-Pugh class B or C) Congestive heart failure (New York Heart Association (NYHA) class 3 or 4) Current alcohol abuse within 30 days of surgery (>4 standard servings daily for men, >3 standard servings daily for women) Type 1 diabetes Received contrast dye within 48 hours of surgery Vulnerable populations: Children, pregnant women, neonates, decisionally impaired adults, prisoners - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 99 Years - StdAgeList: Adult, Older Adult
EUS Guided Drainage of Post Pancreatitis Pancreatic Fluid Collection
Status: Not yet recruiting

The number as well as the caliber of plastic stents used for EUS-guided PFC drainage are controversial in current practice [Lin et al., 2014]. The timing of necrosectomy in WOPN drainage continues to be debated. To date, no comparative studies have been conducted to investigate the ideal timing for stent removal. Thus, the aim of our study is to:

Assess the technical success rates, clinical success rates and potential complications of the different techniques for the best drainage of PFCs as regard type, caliber and number of plastic stents and ideal timing for stent removal.
Compare between early vs late intervention for complete endoscopic necrosectomy of WOPN as regard technical success rates, clinical success rates, potential complications and number of sessions needed.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Symptomatic sterile PFCs; symptoms include persistent abdominal pain, ileus, and gastric outlet obstruction with or without fever. Proven or suspected infected PFCs with or without the presence of necrosis. Patients with pancreatic pseudocyst that unresolved for at least 6 weeks after the last episode of pancreatitis and making compression on surrounding organs such as common bile duct (CBD), portal vein (PV).  Exclusion Criteria:  Patient refusal. Patients with major comorbidities being unfit for general anesthesia. Patients with moderate to marked ascites. Patients with bleeding tendencies and impaired coagulation profile. Patients with proven or suspected malignant pancreatic neoplasms. - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult
The Effectiveness of Virtual Reality on Anxiety Reduction in Women Undergoing Elective Egg Cryopreservation.
Status: Recruiting

A randomized trial assessing the effectiveness of virtual reality exposure prior to an oocyte retrieval procedure in terms of anxiety level .

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients before egg retrieval for social reasons (elective egg freezing)  Exclusion Criteria:  Use of any medications for pain relief/ anti -anxiety /anti -depressants medication generally or prior to the intervention  If suffers from any condition that Use of VR is not recommended:  Risk for seizures Sensitivity to ﬂashing light/motion Predisposing to nausea/dizziness (vertigo, etc.) Any injury to the eyes/face/neck that would limit the use of the hardware, including blindness. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - StdAgeList: Child, Adult, Older Adult
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
Status: Recruiting

The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 4 to 10 Diagnosis of Duchenne muscular dystrophy with a specific genetic change amenable to exon 51 skipping Able to walk Not requiring assistance from a ventilator to breathe Currently on consistent doses of steroid treatment for the last 12 weeks  Exclusion Criteria:  The participant will have some initial clinical labs and studies to assess baseline level of heart and lung function. Treatment with an exon skipping therapy within 12 weeks prior to the first visit. Any history of treatment with gene therapy - HealthyVolunteers: No - Gender: Male - MinimumAge: 4 Years - MaximumAge: 10 Years - StdAgeList: Child